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This review summarises and discusses significant aspects of
recently published studies on patient treatment in advanced
breast cancer and on biomarkers in breast cancer. In recent
years, a large number of drugs for all molecular subtypes have
been developed up to phase III trials. With regard to immune
checkpoint inhibitors in metastasised breast cancer, the re-
cent discussion has centred on the best candidate for com-
bined chemotherapy. The oral taxanes could become a new
type of oral chemotherapies. There is a growing body of data
on biomarkers for the use of CDK4/6 inhibitors, which could
also signify further development for other molecular sub-
types. New substances have been developed for metastatic
HER2+ breast cancer that still result in good remission even
after massive prior treatment and/or cerebral metastasis.
Similarly, knowledge is growing about targeted therapies with
antibody-drug conjugates (ADC) against Trop-2, which could
bolster our therapeutic armoury in triple-negative breast can-
cer (TNBC). In addition, the clinical focus is on understanding
how to maintain fertility after breast cancer treatment. Here,
pooled analyses provide new insights.
ZUSAMMENFASSUNG
In dieser Übersichtsarbeit werden relevante Aspekte kürzlich
veröffentlichter Studien zur Behandlung von Brustkrebs-
patientinnen in fortgeschrittenen Stadien sowie zu Biomar-
kern beim Mammakarzinom zusammenfassend dargestellt
und diskutiert. In den letzten Jahren wurde eine Vielzahl von
Medikamenten für alle molekularen Subtypen bis zu Phase-
III-Studien entwickelt. In Bezug auf die Immuncheckpoint-In-
hibitoren wurde in letzter Zeit für die metastasierte Situation
der optimale Chemotherapie-Kombinationspartner dis-
kutiert. Mit oralen Taxanen könnte sich eine neue Art von ora-
len Chemotherapien etablieren. Die Datenlage zu Biomarkern
für die Anwendung der CDK4/6-Inhibitoren wächst, was auch
eine Weiterentwicklung für andere molekulare Subtypen be-
deuten könnte. Beim HER2+, metastasierten Mammakarzi-
nom wurden neue Substanzen entwickelt, die auch nach mas-
siver Vorbehandlung und/oder zerebraler Metastasierung
noch gute Remissionen zeigen. Ebenso wächst das Wissen
um zielgerichtete Therapien mit Antikörper-Wirkstoff-Kon-
jugaten (ADC) gegenTrop-2, die bei triple-negativen Mamma-
karzinomen (TNBC) eine therapeutische Bereicherung bedeu-
ten könnten. Des Weiteren steht das Verständnis des Fertili-
tätserhaltes nach einer Brustkrebserkrankung im klinischen
Fokus. Hier schaffen gepoolte Analysen einen neuen Einblick.
GebFra Science | ReviewIntroduction
This review summarises the latest data on the treatment of pa-
tients with advanced breast cancer and on new biomarkers. It also
reports a large pooled analysis of fertility and pregnancy after
breast cancer treatment. This type of therapeutic impact on qual-
ity of life plays a special role in the ever-improving therapies es-
tablished in recent years [1–6]. This paper considers full publica-
tions and presentations at the current major cancer and breast
cancer meetings such as ESMO (European Society for Medical On-
cology) 2020 and SABCS (San Antonio Breast Cancer Symposium)
2020.540 Ditsch N et al.Treatment of Patients with Metastatic
Breast CancerChemotherapy agents partnered with immune
checkpoint inhibitors (KEYNOTE-355)
Publication of the IMpassion131 [7] and IMpassion130 trial [8]
raises the question of which chemotherapy agents would best be
partnered with anti-PD‑1/PD‑L1 therapy. More data to clarify this
issue are of particular interest here. The IMpassion130 trial com-
pared first-line therapy with nab-paclitaxel and atezolizumab to
nab-paclitaxel monotherapy in patients with advanced TNBC.
Both progression-free survival and overall survival in PD‑L1-posi-
tive patients improved [9]. The IMpassion131 trial employed pac-
litaxel dissolved with Cremophor as a combination agent rather
than Nab-paclitaxel and failed to meet its primary endpoint (i.e.,
improvement in PFS [Progression Free Survival]). AtezolizumabUpdate Breast Cancer… Geburtsh Frauenheilk 2021; 81: 539–548 | © 2021. The author(s).
thus failed to provide any further benefit in this trial compared
with paclitaxel therapy alone [7]. This even led to a warning from
the US Food and Drug Administration (FDA) against combining
atezolizumab with paclitaxel. However, both studies need to be
studied in more detail. In the IMpassion130 study, almost 40% of
patients did not receive adjuvant or neoadjuvant treatment, i.e.,
they were treatment-naïve patients. Moreover, no patients were
enrolled in the trial who metastasised within 12 months following
adjuvant or neoadjuvant treatment. The number of patients with
PD‑L1-positive tumour in the IMpassion131 trial was relatively
low, with 100 patients in each arm. In addition, 30% of the pa-
tients in this study showed de novo metastases, i.e., they were
also treatment-naïve, while 70% of the patients had undergone
prior treatment. Since about half of the patients had received tax-
anes or anthracyclines, the question arises as to what the remain-
ing 20 patients were treated with. This data can only be extracted
from the final publications.
Recently, data from the KEYNOTE-355 trial was presented,
which was able to provide further insight into this issue. The KEY-
NOTE-355 trial compared a combination therapy of chemother-
apy plus pembrolizumab with chemotherapy alone. Chemother-
apy comprised either nab-paclitaxel (31.6%), paclitaxel (13.5%)
or gemcitabine/carboplatin (54.9%), as preferred by the physi-
cian. In the overall study, adding pembrolizumab to chemother-
apy benefited progression-free survival in the group of patients
with a CPS score for PD‑L1 of ≥ 10, with a hazard ratio (HR) of
0.65 (95% CI: 0.49–0.86) [10]. In the chemotherapy partner sub-
groups, the HR was 0.57 (95% CI: 0.34–0.95) for nab-paclitaxel,
0.33 (95% CI: 0.14–0.76) for paxlitaxel and 0.77 (95% CI: 0.53–
1.11) for gemcitabine/carboplatin [11]. Similar results were seen
for patients with a CPS score of ≥ 1 and in the overall trial popula-
tion. Thus, KEYNOTE-355 did not demonstrate that the combina-
tion partner nab-paclitaxel vs. paclitaxel made a difference in the
efficacy of pembrolizumab.
Whether the three trials (IMpassion130/131 and KEYNOTE-
355) can generally be compared with each other with regard to
this question will only become clear once sufficient follow-up time
for overall survival is available from all trials. It should be noted
that the effect of the immune checkpoint inhibitors was only
shown with a treatment-free interval of more than 12 months; in
the KEYNOTE-355 trial, no effect was shown with a treatment-free
interval of less than 12 months, and the IMpassion130 and -131
trials, too, only enrolled patients who had not undergone treat-
ment for at least 12 months since the end of adjuvant chemother-
apy.
Oral taxanes
A new oral formulation of paclitaxel was reported at SABCS 2019
a year ago [12]. Only small amounts of paclitaxel are absorbed
orally because it is removed from the cell by the P-glycoprotein
pump (P‑gp) [13]. Specific inhibition of P‑gp with the agent en-
cequidar increases the absorption of oral paclitaxel. In the phase
III KX-ORAX-001 trial, 360 patients were randomised 2 :1 to
treatment with oral paclitaxel plus encequidar or to treatment
with intravenous paclitaxel. Eligible were patients with advanced
breast cancer who had not been treated with a taxane within the
last year [14]. In both groups, most patients had ER+/HER−Ditsch N et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 539–548 |© 2021. Thebreast cancer (56%/49%). The primary endpoint of the trial was
to demonstrate an improvement in overall response rate with the
encequidar combination. In the treatment arm with oral taxane,
a response was seen in 40.4% of cases, whereas in the group with
parenteral taxane this was true in only 25.6% of patients
(p = 0.005). This difference was statistically significant
(p = 0.005). A 2019 analysis revealed no difference in PFS with
an HR of 0.76 (95% CI: 0.551–1.049). However, an HR of 0.684
(95% CI: 0.475–0.985) demonstrated a benefit in terms of overall
survival for the oral taxane. In terms of side effects, neuropathies
≥ grade 2 in particular occurred less frequently with the oral tax-
ane at 7.6 vs. 31.1% with the intravenous taxane. Alopecia was
also observed less frequently. Diarrhoea, nausea and vomiting
occurred more frequently [14]. Analyses of this trial conducted
in Central and South America with a longer follow-up period
have now been presented [14]. The analysis regarding PFS now
reached statistical significance (HR: 0.739; 95% CI: 0.561–
0.974). Overall survival also yielded results similar to those of
the primary analysis (HR: 0.735; 95% CI: 0.556–0.972). The com-
bination of oral taxane and encequidar is currently (March 2021)
under review by the US Food and Drug Administration (FDA).
Another oral taxane is tesetaxel. It is a modified taxane that is
not eliminated from the cell by the P‑gp and can therefore also be
administered orally. The oral bioavailability is 56%. In addition, te-
setaxel is markedly more soluble than paclitaxel and docetaxel
[15]. Dosed at 27mg/m2, it is taken once every 3 weeks without
premedication. Recently, the outcomes of the phase III CONTESSA
trial were reported. This trial had enrolled ER+/HER2− patients
who had received no or just one line of chemotherapy in the meta-
static setting. In addition, the (neo)adjuvant situation called for
treatment with a taxane. Any number of prior endocrine treat-
ments were accepted. Patients were randomised 1 :1 to receive
treatment with tesetaxel plus capecitabine or capecitabine alone.
The primary endpoint of the trial was PFS. Secondary endpoints of
the trial included overall survival and overall response rate. Most
of the patients enrolled had not received any prior treatment in
the metastatic setting (93%). Thus, the study population com-
prised mainly patients who received their first treatment in the
metastatic setting.
The primary endpoint of the trial was met. With a median fol-
low-up of 13.9 months, the addition of tesetaxel improved me-
dian progression-free survival from 6.9 (95% CI: 5.6–8.3) to 9.8
(95% CI: 8.4–12.0) months. The HR was 0.716 (95% CI: 0.573–
0.895; p = 0.003) in favour of tesetaxel plus capecitabine [15]. It
is not surprising that combined treatment is superior to mono-
therapy in terms of response rate and progression-free survival.
Whether these promising results become relevant for clinical
practice depends on the data on overall survival, which have not
been analysed so far because the number of events is too low.
Neuropathy grade III–IV developed in 5.9% of patients treated
with tesetaxel [15].
According to a press release, however, further approval of the
agent tesetaxel is not being pursued. Reasons were not initially
given [16].541author(s).




Comparison of molecular subtype
vs. Luminal A group in patients
treated with ribociclib + endocrine
therapy
Comparison of molecular subtype
vs. Luminal A group in patients
treated with endocrine mono-
therapy
Hazard Ratio p-value Hazard Ratio p-value Hazard Ratio p-value
Luminal A 0.63 < 0.001 Reference Reference
Luminal B 0.52 < 0.001 1.17  0.35 1.68  0.00055
HER2 enriched 0.39 < 0.001 1.76  0.00082 1.47 < 0.0001
Basal-like 1.15  0.7672 5.1 < 0.0001 3.05  0.004
Normal-like not shown 0.98  0.93 1.69  0.0025
* The hazard ratio differences were tested with an interaction variable. The differences were statistically significant (p = 0.045).
GebFra Science | ReviewSome new substances in the treatment of advanced
breast cancer have not been convincing
Even though significant progress has been made with numerous
agents in recent years, there are still prominent examples of trials
in which the compounds studied failed to achieve any improve-
ment in efficacy.
One such example is the HDAC (histone deacetylase) inhibitor
entinostat.
Following promising data from a randomised phase II trial for
patients with advanced HR+/HER2− breast cancer, which demon-
strated that both PFS and OS improved with the addition of enti-
nostat to exemestane [17], a phase III E2112 trial was con-
ducted for confirmation. Eligible for enrolment were patients with
HR+/HER2− advanced breast cancer who had progressed on a
non-steroidal aromatase inhibitor and who had not received more
than one prior chemotherapy. 608 patients received either
exemestane plus placebo or exemestane plus entinostat. About
one third of the patients had been treated with a CDK4/6 inhibitor
before enrolment. The trial was negative. No difference in either
PFS or OS was seen between the treatment arms with relatively
short median PFS times of 3.3 and 3.1 months. Median overall sur-
vival was 23.4 versus 21.7 months.
The other trial, which also followed a positive randomised
phase II trial for patients with advanced TNBC, was the IPATu-
nity130 phase III trial [18]. This trial studied the Akt inhibitor ipa-
tasertib. The Akt kinase signalling pathway is one of the main sig-
nal transduction pathways from the cell surface to the nucleus. It
can be activated by a variety of molecular changes such as PTEN
loss, PI3K mutations, or AKT1 mutations. Since approximately
35% of all TNBC tumours exhibit one of these molecular altera-
tions, targeted therapy may be important for a clinically signifi-
cant group of patients. The phase II LOTUS trial published previ-
ously reported an HR of 0.60 (95% CI: 0.37–0.98) [19] for PFS in
the overall population (N = 93). In the group of patients with
PTEN/AKT1/PIK3CA alteration (n = 33), the HR was 0.44 (95% CI:
0.20–0.99) [19]. The IPATunity130 trial now attempted to repli-
cate the outcomes through a randomised phase III trial. It studied
255 patients with advanced TNBC and a PIK3CA/AKT1/PTEN alter-
ation in the first line of therapy, i.e., without prior treatment of542 Ditsch N et al.the advanced breast cancer. Patients were treated with either pac-
litaxel weekly 80mg/m2 or paclitaxel weekly plus 400mg ipata-
sertib per day for 21 days followed by a week off. With regard to
the primary endpoint PFS at a median follow-up time of
8.3 months, no difference was seen between both treatment
arms. Median PFS times were short at 6.1 (95% CI: 5.5–9.0)
months in the paclitaxel arm and 7.4 months (95% CI: 5.6–8.5)
in the ipatasertib plus paclitaxel arm (HR: 1.02; 95% CI: 0.71–
1.45).
Both trials emphasise the importance of validating initially
good efficacy signals in larger phase III trials.Biomarker
PAM50 in treatment with CDK4/6 inhibitors
in the metastatic setting (ML2,3,7).
Combining endocrine treatment with CDK4/6 inhibitors is the
standard of care for first line therapy in patients with advanced
ER+/HER2− breast cancer. So far, there are no known prognostic
or predictive markers, except for hormone receptor status, that
could predict a greater or lesser benefit of endocrine monother-
apy or combined treatment with CDK4/6 inhibitors plus endocrine
therapy. It is known that the histopathological determination of
the oestrogen receptor, progesterone receptor, HER2 status, and
the grading can roughly classify the patients into intrinsic sub-
types. However, in over 20% of cases, this assessment does not
match the molecular subtype [20]. Since CDK4/6 inhibitors have
demonstrated their efficacy, particularly in molecular luminal
and HER2-amplified cell lines [21], one can reasonably pose this
question in clinical populations as well. This has now been under-
taken through a pooled analysis of the MONALEESA trials (MONA-
LEESA-2 [22], MONALEESA-3 [23,24], MONALEESA-7 [25,26])
[27]. In1160 of the total population of 2066 patients, it was possi-
ble to analyse a tumour sample with the PAM50 classifier with re-
gard to the molecular subtype. Of these 1160 patients, 47% had
subtype luminal A, 24% had subtype luminal B, 13% had subtype
HER2, 3% had subtype Basal-like and 14% had subtype Normal-
like. The HR for these groups are listed in ▶ Table 1. The 13% ofUpdate Breast Cancer… Geburtsh Frauenheilk 2021; 81: 539–548 | © 2021. The author(s).
Trop-2 high | H-score: 200–300 Trop-2 medium | H-score: 100–200 Trop-2 low | H-score: < 100
SG (n = 85) SG (n = 39) SG (n = 27)TPC (n = 72) TPC (n = 35) TPC (n = 32)
Median PFS, months (95% CI)
Assessed in brain metastases-negative population. Trop-2 expression determined in archival samples by validated immunohistochemistry assay and H-scoring.
H-score: histochemical score, PFS: progression-free survival, SG: sacituzumab govitecan, TPC: treatment of physician’s choice, Trop-2: trophoblast cell surface antigen-2.






























SG – Trop-2 high
SG – Trop-2 medium
SG – Trop-2 low
TPC – Trop-2 high
TPC – Trop-2 medium
TPC – Trop-2 low
▶ Fig. 1 Progression-free survival in the ASCENT trial by Trop-2 expression [31].patients in the HER2 subgroup benefited most from treatment
with ribociclib (HR: 0.39; p < 0.001). The few patients with the Ba-
sal-like subtype (3%) did not benefit from treatment with riboci-
clib (HR: 1.15; p = 0.7672) [27]. Thus, these results confirm the
preclinical data on CDK4/6 inhibitors [21]. Although interesting
data was generated by this analysis, it is unlikely that it will affect
clinical practice. However, the outcomes could be used to identify
suitable patient populations for treatment once CDK4/6 inhibitors
are introduced into adjuvant therapy.
Biomarker analysis of the ASCENT trial
in HER2-positive metastatic breast cancer
One class of substances that has significantly enhanced the thera-
peutic landscape since its approval for advanced HER2-positive
breast cancer and for patients without complete response after
neoadjuvant anti-HER2 chemotherapy are the so-called antibody
drug conjugates (ADCs). A linker binds cytotoxic substances to
antibodies. This allows not only target molecules driving the prog-
nosis of cancer to be a treatment target, but also molecules only
found on the cell surface as “anchors”. This was shown, for exam-
ple, with the ADC trastuzumab-deruxtecan (T‑DXd), which also
demonstrated its efficacy in patients with low HER2 expression
[28]. In patients with triple-negative breast cancer, the ADC saci-
tuzumab govitecan (SG) represents a new therapy with high effi-
cacy even after some prior therapies [29,30]. It binds to the tar-
get molecule Trop-2, which has been detected in patients withDitsch N et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 539–548 |© 2021. Thebreast cancer. Compared with chemotherapy as preferred by the
physician, sacituzumab govitecan significantly improved both PFS
(HR: 0.41) and overall survival (HR: 0.48), as shown in the ASCENT
trial [29]. In this context, it is interesting to ask whether the ex-
pression levels of Trop-2 might affect the efficacy of the ADC. Hy-
pothetically, any effect on efficacy should not be significant. A
biomarker analysis of the ASCENT trial addressed precisely this
question. In addition, the TNBC patient population was also tested
for BRCA1/2 mutations [31]. Trop-2 expression was determined
by immunohistochemistry and patients were classified into high,
medium and low Trop-2 expression groups. The analysis included
468 patients altogether. Trop-2 expression was assessed in 290 pa-
tients, of whom 54.1% showed high expression, 25.5% medium
expression and 20.3% low expression. Of the 292 patients
screened for BRCA1/2 mutations, 11.6% presented with a muta-
tion. In the group of patients who had been treated with chemo-
therapy, Trop-2 expression did not impact prognosis (median PFS
times: 2.5 months [high expression]; 2.2 months [medium ex-
pression]; 1.6 months [low expression]). In the sacituzumab govi-
tecan arm, the difference between the medium and high Trop-2
expression groups was also small. In patients with high Trop-2 ex-
pression, the median PFS was 6.9 months (95% CI: 5.8–7.4) and in
those with intermediate expression 5.6 months (95% CI: 2.9–8.2).
However, low expression correlated with a median PFS of only
2.7 months (95% CI: 1.4–5.8) [31] (▶ Fig. 1). Nevertheless, PFS
improved significantly in all groups. BRCA1/2 status did not affect543author(s).
▶ Table 2 Overall survival times for patients with and without CTC
elimination during observation and the corresponding hazard ratios
(from [35]).
CTC status at treatment baseline/
























HR 1 0.41 (95% CI: 0.32–0.52)
GebFra Science | Reviewthe efficacy of sacituzumab govitecan [31]. This analysis thus illus-
trates that principle treatment with an appropriate ADC may also
be effective in tumours with lower target molecule expression.
Biomarkers as selection criterion in patients
undergoing endocrine therapy
Many of the (adjuvant) trials on multigene tests or other biomark-
ers published in recent years employed a trial design investigating
whether different characteristics in a patient population resulted
in similar prognoses, rather than comparing different treatment
regimens, including the endocrine part of the ADAPT trial [32].
The ADAPT trial on HR+/HER− early breast cancer with 0–3 af-
fected lymph nodes compared the following patients:
A. Patients with an Oncotype DX® Recurrence Score of 0–11 at
initial diagnosis (n = 868)
B. Patients with an Oncotype DX Recurrence Score of 12–25 at
initial diagnosis and a decline in Ki‑67 to ≤ 10% at re-biopsy
after 3 weeks of preoperative endocrine treatment (n = 1422)
Due to the difference in patient selection, both groups differed in
most characteristics. The authors emphasised that this was not a
comparison of groups in a randomised trial. Both groups had a
comparable probability of relapse-free survival. In group A, the
probability of disease-free survival at 5 years was 93.9% (95% CI:
91.8–95.4), whereas in group B it was 92.6% (95% CI: 90.8–94.0).
It was ruled out that the difference with a one-tailed 95% confi-
dence interval was greater than the prespecified 3.3%. Similar
outcomes were obtained for the overall survival analysis, the dis-
tant metastasis-free survival analysis, and for patients under the
age of 50 years and those over the age of 50 years. The non-infe-
riority of group B, independent of menopausal status, demon-
strated that dynamic Ki-67 assessment can close a prognostic
gap in premenopausal breast cancer patients with limited lymph
node involvement and an RS of 12–25 (see RxPONDER trial).
The only variables of prognostic significance in the group of
patients analysed were lymph node status (0–2 malignant lymph
nodes vs. 3 lymph nodes), tumour stage (pT2–4 vs. pT0–1) and
progesterone receptor expression (ordinal variable with 10% in-
crements) [32]. Thus, it can be stated that in the heterogeneous
group recruited in the ADAPT trial, only lymph node status, tu-
mour size and progesterone receptor expression were indepen-
dent predictors of prognosis.
CTC as a marker for monitoring treatment
in metastatic breast cancer
One biomarker that has been studied for decades is circulating tu-
mour cells in the blood (CTCs) [33, 34]. In both patients with early
breast cancer and those with advanced disease, the presence of
CTCs correlates with unfavourable prognosis. One question aris-
ing from this observation is whether the presence of CTCs in the
course of the disease may be tapped as a monitoring marker for
treatment. An international pooled analysis with 4079 patients
addressing this issue has now been presented [35]. The paper fo-
cused on trials in which CTC measurements were available prior to
as well as during the treatment. This international analysis in-
cluded a total of 14 trials. For the overall population and for the
molecular subtypes, groups of patients who continued to have544 Ditsch N et al.detectable CTCs both at baseline and during follow-up were com-
pared with patients who were also CTC-positive at baseline but for
whom CTCs were no longer detected during follow-up. ▶ Table 2
summarises the findings. Both in the overall population and the
subgroups (HR-positive, HER2-positive, TNBC), the elimination of
CTCs during the treatment roughly doubled median overall sur-
vival. This illustrates that CTC levels during the treatment course
can provide a very good indication of the response to treatment
and its effect on overall survival. Not unlike with neoadjuvant
therapy, the question is whether monitoring patients with positive
CTCs prior to treatment and an early change in treatment may
benefit those patients with persistent CTCs. However, before
these ideas can be applied to routine practice, the trial outcomes
must be awaited so that this promising technology does not give
rise to false expectations or even endanger patients.
Breast Cancer Index and patient selection
for extended adjuvant endocrine therapy
The aTTom trial (“Adjuvant Tamoxifen Treatment Offer More”)
compared 5 years of adjuvant tamoxifen therapy with 10 years of
tamoxifen [36]. A retrospective analysis of this trial involving 1822
of 6956 patients employed a multigene expression test, which
had previously been validated as a strong prognostic factor in sev-
eral trials. The BCI test comprises two components, the H/I ratio
(ratio of the gene expression of HOXB13: IL17BR) and the Molec-
ular Grade Index (MGI), which maps tumour proliferation with
5 genes (BUB1B, CENPA, NEK2, RACGAP1, RRM2) [37,38]. More-
over, different predictions can be made for the prognosis of pa-
tients who underwent treatment with tamoxifen for 5 and
10 years, respectively.
It was analysed whether the H/I ratio (BCI[H/I]) could help to
identify patients who would benefit from extending endocrineUpdate Breast Cancer… Geburtsh Frauenheilk 2021; 81: 539–548 | © 2021. The author(s).
▶ Table 3 Relative risks of pregnancy after malignant disease [40].








Hodgkin lymphoma 0.62 0.47–0.82
All types 0.65 0.55–0.77
Liver 0.65 0.19–2.26




bold = estimates for breast cancertherapy to 10 years. It was shown that the predicted prognosis for
patients treated with 5 years of tamoxifen treatment differed sig-
nificantly from patients treated with 10 years of tamoxifen
(HR = 0.35; 95% CI 0.15–0.86; p = 0.014). Thus, the BCI(H/I)
would be the first test capable of identifying patients who would
benefit from extended anti-hormone therapy. However, it must
be noted that since the aTTom trial had been conducted, far fewer
patients have been treated with adjuvant tamoxifen both in the
premenopausal and especially in the postmenopausal setting.
The data from the MonarchE trial could also mean that in the fu-
ture adjuvant treatment could include other active substances.
The possible significant predictive value of the BCI(H/I) would
then have to be explored again.
Progress in the treatment of metastatic
HER2-positive breast cancer
Already in 2019 at the San Antonio Breast Cancer Congress
(SABCS), trial results were presented for two agents that still show
impressive activity after prior treatment of metastatic HER2-posi-
tive breast cancer with T‑DM1: The HER2-specific tyrosine kinase
inhibitor tucatinib and the antibody-drug conjugate tastuzumab-
deruxtecan (T‑DXd).
In a prospective phase II trial, 612 patients with metastatic
HER2+ breast cancer and ≥ 2 prior treatments including T‑DM1
were randomised 2 :1 to capecitabine/trastuzumab/tucatinib ver-
sus capecitabine/trastuzumab/placebo. 48% of the patients had
brain metastases [39]. The addition of tucatinib resulted in a sig-
nificant benefit in both PFS and OS. Of particular note is that in the
subgroup of patients with cerebral metastasis, DFS after one year
was 24.9% in the tucantinib group and 0% in the control group. At
the last SABCS in December 2020, E. Hamilton for the HER2CLIMB
trial group confirmed the benefits for the combination with tuca-
tinib in terms of DFS and OS, regardless of hormone receptor sta-
tus and also in patients with cerebral metastases. Adverse reac-
tions such as diarrhoea and hand-foot syndrome were more fre-
quent in the experimental arm. Approval of tucatinib in Germany
is expected in the next few weeks and the drug is currently avail-
able in Germany through a compassionate use programme.
In the single-arm phase II DestinyBreast01 trial the antibody-
drug conjugate trastuzumab-deruxtecan (T‑DXd) displayed a
good response of 60.9% and a PFS of 14.8 months in 184 patients
with metastatic HER2-positive breast cancer (13% of whom had
stable brain metastases) after prior T‑DM1 treatment [28]. Apart
from mild to moderate haematological and gastrointestinal side
effects, interstitial lung disease (ILD) was observed in 13.6% of all
cases and ≥ 3rd degree in 3%. A 20.4-month follow-up yielded a
PFS benefit, which increased to 19.4 months in the last analysis.
The rate of pulmonary complications did not rise any further.
Thus, ILD does not have a cumulative effect, but it does require
interdisciplinary management and good patient education and
selection. T‑DXd approval in Germany depends on the outcome
of the two ongoing phase III trials (DestinyBreast06 trial,
NCT0449442, and DestinyBreast03 trial, NCT03529110).Ditsch N et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 539–548 |© 2021. TheTreatment Management and Patient Concerns
Fertility following breast cancer
Women who develop breast cancer at a young age often face the
question of pregnancy after the disease with all its treatments
(chemotherapy, radiotherapy, targeted therapy, and endocrine
therapy). An international working group has conducted a sys-
tematic review with a meta-analysis. They were able to identify a
total of 39 studies that could be analysed for the chance of preg-
nancy, pregnancy complications and maternal mortality.
48513 breast cancer patients were compared with 3289113
healthy women regarding the probability of pregnancy following
breast cancer. The relative risk of pregnancy was 0.40 (95% CI:
0.32–0.49). In other words, women who had developed breast
cancer were 60% less likely to become pregnant than women in
the healthy comparison population. The comparison with other
types of cancer, shown in ▶ Table 3 [40], was interesting. Here it
is noteworthy that only patients with cervical cancer had a smaller
chance of pregnancy after malignant disease than patients with
breast cancer. All other tumour entities had a better chance of
pregnancy. With regard to the rate of pregnancy complications,
a comparison of 3240 breast cancer patients and more than
4800000 women from healthy controls revealed that the risk of
caesarean section was increased with a relative risk of 1.14 (95%
CI: 1.04–1.25), of low birth weight (RR: 1.50; 95% CI: 1.31–1.73)
and of preterm birth (RR: 1.45; 95% CI: 1.11–1.88). However, the
risk of congenital anomalies had an RR of 1.68 (95% CI: 0.89–
2.98). Due to the small number of cases, though, this risk was
probably not statistically significant (p = 0.112). Further subgroup
analyses revealed that the risk of low birth weight was higher in
the group of patients who had received chemotherapy for breast545author(s).
GebFra Science | Reviewcancer (RR: 1.662; 95% CI: 1.08–2.42) versus patients who did not
undergo chemotherapy (RR: 1.05; 95% CI: 0.77–1.43) [40].
In terms of relapse-free survival/overall survival (OS) after
breast cancer, 2003 (DFS)/3261 (OS) breast cancer patients with
a pregnancy post disease were compared with approximately
38000 (PFS)/52000 (OS) patients without pregnancy. In general,
pregnancy had protective effects on survival. The HR for DFS was
0.73 (95% CI: 0.56–0.94) and 0.56 (0.46–0.67) for overall survival.
Moreover, these effects were largely independent of other disease
parameters such as nodal status and chemotherapy.Outlook
For some treatments with demonstrated definite efficacy, such as
the CDK4/6 inhibitors, the next stage will be to establish and
understand any sequences with other treatment regimens, as well
as to possibly refine the treatment for other molecular subtypes or
treatment settings. With the ADC sacituzumab govitecan, anoth-
er compound from this drug class seems to be gaining a foothold.
Tucatinib and trastuzumab-deruxtecan broaden the therapeutic
spectrum in metastatic HER2-positive breast cancer.
The insights into biomarkers are broadening our understand-
ing of the mode of action and the potential applications of ADCs
in breast cancer. Some expectations regarding Akt kinase inhib-
itors and HDAC inhibitors could not be confirmed in phase III tri-
als. Nevertheless, the development of new biomarkers and treat-
ment regimens for patients with advanced breast cancer is pro-
gressing rapidly, and the therapeutic options are expected to
evolve.
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